Health · 1 views
Experimental drug shows potential for hard-to-treat heart disease
An experimental drug has been shown to improve symptoms, exercise capacity and heart failure status in patients with an inherited heart disease, according to a pair of newly published studies.
AI Summary
Two recent studies published in The New England Journal of Medicine and Circulation examined aficamten, a next‑generation cardiac myosin inhibitor, in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The research found that aficamten improved patients’ symptoms, increased exercise capacity, and improved heart failure status. The drug targets myosin, a protein in the heart muscle’s contractile unit, to reduce abnormal contractility associated with the inherited disease. The findings suggest a potential new therapeutic option for individuals with nHCM.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- The Guardian view on Lucy Letby: Thirlwall should have waited for the pending case review | EditorialContinue reading
- Having a bad hair day? My new research might helpContinue reading
- Ministers vow sweeping NHS changes after ‘devastating’ report on Lucy Letby hospitalContinue reading
- Dengue‑carrying mosquitoes expand their reach into new territories—including FloridaContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow